LIFE

#ACC21

AMERICAN COLLEGE of CARDIOLOGY

Trial Description: Patients with advanced HFrEF were randomized in a 1:1 fashion to either sacubitril/valsartan or valsartan. Patients were followed for 24 weeks.



RESULTS

- Primary endpoint, area under the curve for the proportional change in the ratio of NT-proBNP to baseline, for sacubitril/valsartan vs. valsartan: p = 0.45
- Days alive, out of hospital, or free from HF events: 103.2 vs. 111.2 days (p = 0.45)
- CV death or hospitalization for HF: HR 1.32, 95% CI 0.86-2.03 (p = 0.20)
- Hypotension: 17% vs. 12% (p = 0.16); hyperkalemia: 17% vs. 9% (p = 0.035)

CONCLUSIONS

- Sacubitril/valsartan did not reduce NT-proBNP or clinical outcomes among patients with advanced HFrEF and comorbidities
- Hyperkalemia was higher with sacubitril/valsartan

Presented by Dr. Douglas L. Mann at ACC.21